Evidence map›Paper›PMID 41245217›Full record

ArticleMolecular therapy. Methods & clinical development2025

Harnessing DNA barcoding to enhance and sustain polyclonality in gene-edited hematopoietic stem cells.

Isabel Ojeda-Perez, Andrés Bustos, Sridhar Selvaraj, Sara Fañanas-Baquero, Omaira Alberquilla-Fernandez, Luis-Javier Serrano, Jose Bonafont, Aida Garcia-Torralba, Raul Torres-Ruiz, Sandra Rodriguez-Perales and 7 more

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Isabel Ojeda-PerezCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Andrés BustosScientific IT Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Sridhar SelvarajDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Sara Fañanas-BaqueroCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Omaira Alberquilla-FernandezCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Luis-Javier SerranoDanaus Pharmaceuticals, Madrid, Spain/DanausGT Biotechnology, Wuxi, China.
Jose BonafontDanaus Pharmaceuticals, Madrid, Spain/DanausGT Biotechnology, Wuxi, China.
Aida Garcia-TorralbaCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Raul Torres-RuizCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Sandra Rodriguez-PeralesMolecular Cytogenetics & Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain.
Valeri LangViralgen SL, Paseo Mikeletegi, 8, 20009 San Sebastian, Spain.
Cesar TriguerosViralgen SL, Paseo Mikeletegi, 8, 20009 San Sebastian, Spain.
Rafael Mayo-GarciaScientific IT Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
Oscar Quintana-BustamanteCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Matthew PorteusDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Rebeca Sánchez-DominguezCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Jose-Carlos SegoviaCell Technology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A challenge in gene editing for hematopoietic stem and progenitor cells (HSPCs) is achieving efficient editing while preserving long-term engraftment and clonal diversity. Tracking edited clones with high resolution is essential to understand the impact of editing on hematopoiesis. We developed a barcoded AAV6 donor template (BC-AAV) to precisely monitor the fate of edited HSPCs following transplantation. Our findings reveal that, despite initial barcode diversity

Indexed as

Adenoassociated viral vectorCRISPR-Cas9DNA BarcodeGene editingHSC clonesKnock-in

Identifiers

PMID41245217
PMCPMC12615287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.